NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Sunday, May 26, 2024 12:30

Description: Virbac 2013
Release 3.92
Canigen Rabies
Species: Cats, Dogs, Ferrets
Therapeutic indication: Immunological veterinary medical products: For dogs, For cats, For ferrets
Active ingredient: Vaccine Antigens
Product:Canigen Rabies
Product index: Canigen Rabies
Qualitative and quantitative composition
Each 1 ml dose contains:
Active substance: Inactivated rabies virus strain Pasteur RIV: ≥ 0.95 AIU* equivalent to ≥ 2 IU
Adjuvant: Aluminium phosphate (adjuvant) 0.60 - 0.88 mg Al3+
Pharmaceutical form
Suspension for injection
Light yellow/orange to slightly red/purple with a whitish sediment.
Clinical particulars
Target species
Dogs and cats.
Indications for use, specifying the target species
For the active immunisation against rabies to reduce clinical signs and mortality.
Onset of immunity: an adequate serological response (≥ 0.5 I.U.) has been demonstrated 2 to 3 weeks after vaccination.
Duration of immunity: 3 years.
Special warnings for each target species
Vaccinate healthy animals only.
The vaccine may not be effective in animals incubating the disease at the time of vaccination.
Some animals may be immunologically incompetent and fail to respond to vaccination. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Special precautions for use
Special precautions for use in animals
The presence of maternal antibodies can interfere with the response to vaccination.
This product should not be administered for at least one month following the administration of hyperimmune serum (anti-serum) or immunosuppressant drugs.
Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration.
Special precautions to be taken by the person administering the medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse Reactions (frequency and seriousness)
Transient local reactions such as non-painful diffuse to firm swellings of approximately 1 cm in diameter may be observed for up to 3 weeks after subcutaneous vaccination.
A transient acute hypersensitivity reaction - with signs that may include, facial oedema, vomiting, pruritus or diarrhoea - may occur shortly after vaccination in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening with additional signs like dyspnoea, collapse, ataxia, muscle tremor and convulsion. If such reactions occur appropriate treatment is recommended.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia or immune-mediated polyarthritis have been reported in very rare cases.
Use during pregnancy and lactation
Can be used during pregnancy in dogs. There are no laboratory data on use during pregnancy in other species, but on basis of field experience, such use is expected to be safe.
Interactions with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with vaccines of the Canigen range containing one or more of the following components: live canine distemper, canine adenovirus, canine parvovirus and canine parainfluenza or live feline viral rhinotracheitis virus, feline calicivirus and feline panleucopenia virus.
Safety and efficacy data are available which demonstrate that Canigen Rabies can be administered on the same day but not mixed with Canigen vaccines containing canine Leptospira interrogans serogroups Canicola and Icterohaemorrhagiae antigens.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amount to be administered and administration route
A single dose inoculation of 1 ml is sufficient irrespective of size, species or breed of animal.
Intramuscular or subcutaneous use.
Sterile equipment should be used for administration. Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Primary course and booster vaccination
Dogs & cats
Primary vaccination age*: 12 weeks or older
Booster vaccination: every 3 years
Route of administration: intramuscularly or subcutaneously
*The primary vaccination may be administered at an earlier age, but then a repeat vaccination must be given at the age of 12 weeks.
Minimum vaccination age in dogs and cats: 4 weeks.
Further information
Limited safety data for ferrets are available from monitoring post vaccination reactions. Ferrets can be vaccinated subcutaneously from 12 weeks of age. An adequate serological response (≥ 0.5 I.U.) has been demonstrated 1 month after vaccination. Ferrets should receive a booster vaccination every 18 months.
Overdose (symptoms, emergency procedures, antidotes) (if necessary)
No effects other than those described above
Withdrawal period(s)
Not applicable
Pharmacological particulars
The vaccine contains inactivated antigens to stimulate active immunity against rabies.
Pharmaceutical particulars
List of excipients
Aluminium phosphate
Di-sodium hydrogen phosphate dihydrate
Sodium dihydrogen phosphate dihydrate
Water for injections
Do not mix with any other veterinary medicinal products except components recommended for use with the veterinary medicinal product listed above.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 4 years.
Special precautions for storage
Store in a refrigerator (2°C to 8°C).
Do not freeze.
Protect from light.
Nature and composition of immediate packaging
Type I glass vial closed with rubber stopper and aluminium cap.
Package sizes:
Cardboard box with 1 x 1 ml, 10 x 1 ml or 50 x 1 ml vials
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived-from the use of such products, if appropriate
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
MSD Animal Health UK Limited
Walton Manor
Milton Keynes
Marketing Authorisation Number
Vm 01708/4521
Significant changes
Date of the first authorisation or date of renewal
Date of first authorisation: 25 October 2005
Date of revision of the text
Date of revision of the text: December 2021
Any other information
Legal category
Legal category: POM-V
GTIN description:--